Australia
· Delayed Price · Currency is AUD Percheron Therapeutics Company Description
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia.
The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications.
Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023.
Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | James Garner |
Contact Details
Address: L30, Collins Place Melbourne, 3000 Australia | |
| Phone | 61 3 9827 8999 |
| Website | PercheronTx.com |
Stock Details
| Ticker Symbol | PER |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ANP4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA | Chief Executive Officer, MD and Director |
| Deborah Ambrosini B.Com., F.C.A. | Company Secretary and Chief Financial Officer |